Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Influenza
Alveo Technologies to develop avian influenza A(H5) test with CDC
By
LabPulse.com staff writers
Under the agreement with the CDC, Alveo Technologies will develop a rapid diagnostic to detect and differentiate between influenza A and B and influenza A/H5, also known as the avian influenza subtype, in humans.
November 14, 2024
Roche launches diagnostic test for 12 respiratory viruses
By
LabPulse.com staff writers
Roche Diagnostics has launched its first test using its new high-throughput technology that enables users of Roche's Cobas analyzers to simultaneously test for 12 respiratory viruses.
September 26, 2024
Alveo develops rapid test for avian flu
By
LabPulse.com staff writers
Diagnostics firm Alveo Technologies has developed a rapid, point-of-need diagnostic for avian influenza that can detect the H5N1 variant based on sequences published from recent human and cattle infections.
July 23, 2024
BARDA awards Moderna $176M for pandemic flu vaccine development
By
LabPulse.com staff writers
The Biomedical Advanced Research and Development Authority (BARDA) has awarded Moderna approximately $176 million for the development of an mRNA-based pandemic influenza vaccine.
July 2, 2024
NIH starts early-phase trial of second-generation universal flu vaccine candidate
By
Nick Paul Taylor
The U.S. National Institutes of Health (NIH) has begun an early-phase clinical trial of its second-generation universal flu vaccine candidate.
September 20, 2023
Moderna’s mRNA flu shot yields promising results in phase III trial
By
LabPulse.com staff writers
Moderna announced that its mRNA flu shot that is in development has met its primary endpoints in a phase III trial, generating a stronger immune response than a commercially available flu vaccine.
September 15, 2023
COVID-19 still associated with higher death risk than flu
By
Elissa Wolfson
VA hospital patients with COVID-19 had a higher risk of death than seasonal influenza patients from fall 2022 to winter 2023.
April 11, 2023
FDA grants 510(k) clearance to DiaSorin for COVID-19 and flu A/B assay
By
Leo O'Connor
The test detects and differentiates influenza A, influenza B, and SARS-CoV-2 viruses to help ensure physicians can recommend the most appropriate treatment for each patient.
March 20, 2023
Cepheid says its influenza assays mitigate impact of mutational drift seen in some tests
By
LabPulse.com staff writers
Two mutations in the matrix genes of the human influenza A virus have been reported to cause matrix gene target failure for several commercial diagnostic tests.
December 8, 2022
Reagent supplier launches antigens for Southern Hemisphere's 2023 flu season
By
LabPulse.com staff writers
The hemagglutinin and neuraminidase antigens were developed in response to flu vaccine formulations the World Health Organization selected for development in the Southern Hemisphere.
November 21, 2022
Virax introduces rapid test kit for RSV, influenza A/B, COVID-19
By
LabPulse.com staff writers
Virax Biolabs announced the distribution of a rapid antigen test kit capable of detecting when individuals have been infected with RSV, Influenza A/B, or COVID-19.
November 3, 2022
University of Illinois spinout Shield T3 launches saliva-based PCR test for COVID, flu, RSV
By
LabPulse.com staff writers
Shield T3, a spinout of the University of Illinois, will offer a triple-virus PCR test kit, in anticipation of increased cases of COVID-19, flu, and RSV this winter.
October 25, 2022
Page 1 of 7
Next Page
